7-3-4-7　ⓔ文献

  1. 国立感染症研究所：感染症発生動向調査事業年報，2020．https://www.niid.go.jp/niid/ja/-idwr-dL/2020.html

  2. Ashida H, Ogawa M, et al: Shigella are versatile mucosal pathogens that circumvent the host innate immune system. Curr Opin Immunol, 2011; 23: 448–455.

  3. Khan WA, Griffiths JK, et al: Gastrointestinal and extra–intestinal manifestations of childhood shigellosis in a region where all four species of Shigella are endemic. PLoS One, 2013; 8: e64097.

  4. Butler T: Haemolytic uraemic syndrome during shigellosis. Trans R Soc Trop Med Hyg, 2012; 106: 395–399.

  5. Christopher PRH, David KV, et al: Antibiotic therapy for Shigella dysentery. The Cochrane database of systematic reviews, 2010; CD006784.

  6. Rahman M, Shoma S, et al: Increasing spectrum in antimicrobial resistance of Shigella isolates in Bangladesh: resistance to azithromycin and ceftriaxone and decreased susceptibility to ciprofloxacin. J Health Popul Nutr, 2007; 25: 158–167.

  7. Heiman KE, Karlsson M, et al: Notes from the field: Shigella with decreased susceptibility to azithromycin among men who have sex with men–United States, 2002–2013. MMWR Morb Mortal Wkly Rep, 2014; 63: 132–133.